Home
Search
Study Topics
Glossary
|
Study 19 of 853 for search of: | Canada, Nova Scotia |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
Astellas Pharma Inc |
---|---|
Information provided by: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00666302 |
A study to compare efficacy of Protopic Ointment to that of Elidel Cream in treating patients with Atopic Dermatitis
Condition | Intervention | Phase |
---|---|---|
Dermatitis, Atopic |
Drug: tacrolimus ointment Drug: pimecrolimus cream |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis |
Enrollment: | 413 |
Study Start Date: | October 2002 |
Study Completion Date: | November 2003 |
Primary Completion Date: | November 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: tacrolimus ointment
topical
|
2: Active Comparator |
Drug: pimecrolimus cream
topical
|
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Birmingham, Alabama, United States, 35205 | |
United States, California | |
San Francisco, California, United States, 94118 | |
United States, Kansas | |
Kansas City, Kansas, United States, 66160 | |
United States, Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
United States, Missouri | |
St Louis, Missouri, United States, 63110 | |
United States, New York | |
New York, New York, United States, 10029 | |
United States, North Carolina | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Cincinnati, Ohio, United States, 45219 | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, Texas | |
San Antonio, Texas, United States, 78229 | |
Dallas, Texas, United States, 75230 | |
United States, Utah | |
Salt Lake City, Utah, United States, 84124 | |
United States, Virginia | |
Norfolk, Virginia, United States, 23507 | |
Canada, Nova Scotia | |
Halifax, Nova Scotia, Canada, B3H 1Z4 | |
Halifax, Nova Scotia, Canada, B3H 1V7 |
Study Director: | Use central contact | Astellas Pharma US, Inc. |
Responsible Party: | Astellas Pharma US, Inc. ( Sr Manager Clinical Trials Registry ) |
Study ID Numbers: | 20-02-004 |
Study First Received: | April 23, 2008 |
Last Updated: | July 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00666302 |
Health Authority: | United States: Institutional Review Board; Canada: Canadian Institutes of Health Research |
Atopic Dermatitis Protopic Elidel |
Hypersensitivity Dermatitis, Atopic Genetic Diseases, Inborn Skin Diseases Hypersensitivity, Immediate |
Skin Diseases, Eczematous Pimecrolimus Tacrolimus Skin Diseases, Genetic Dermatitis |
Anti-Inflammatory Agents Immune System Diseases Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions Analgesics, Non-Narcotic Sensory System Agents |
Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Dermatologic Agents |